287 related articles for article (PubMed ID: 18406875)
1. Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Ramkumar B; Chadha MK; Barcos M; Sait SN; Heyman MR; Baer MR
Cancer Genet Cytogenet; 2008 Apr; 182(2):126-9. PubMed ID: 18406875
[TBL] [Abstract][Full Text] [Related]
2. Mitoxantrone-related acute leukemia in two MS patients.
Pielen A; Goffette S; Van Pesch V; Gille M; Sindic CJ
Acta Neurol Belg; 2008 Sep; 108(3):99-102. PubMed ID: 19115673
[TBL] [Abstract][Full Text] [Related]
3. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.
Ko MW; Tamhankar MA; Volpe NJ; Porter D; McGrath C; Galetta SL
J Neurol Sci; 2008 Oct; 273(1-2):144-7. PubMed ID: 18687447
[TBL] [Abstract][Full Text] [Related]
4. Acquired acute myelogenous leukemia after therapy for acute promyelocytic leukemia with t(15;17): a case report and review of the literature.
Betancourt-García RD; Castro J; Fernández AC; López-Enríquez A; Fradera J; Pacheco E
P R Health Sci J; 2009 Jun; 28(2):146-50. PubMed ID: 19530558
[TBL] [Abstract][Full Text] [Related]
5. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Snijder S; Mellink CH; van der Lelie H
Cancer Genet Cytogenet; 2008 Jan; 180(2):149-52. PubMed ID: 18206542
[TBL] [Abstract][Full Text] [Related]
6. Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.
Ottone T; Hasan SK; Montefusco E; Curzi P; Mays AN; Chessa L; Ferrari A; Conte E; Noguera NI; Lavorgna S; Ammatuna E; Divona M; Bovetti K; Amadori S; Grimwade D; Lo-Coco F
Genes Chromosomes Cancer; 2009 Mar; 48(3):213-21. PubMed ID: 19023877
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.
Sadiq SA; Rammal M; Sara G
Mult Scler; 2008 Mar; 14(2):272-3. PubMed ID: 17986509
[TBL] [Abstract][Full Text] [Related]
8. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Pascual AM; Téllez N; Boscá I; Mallada J; Belenguer A; Abellán I; Sempere AP; Fernández P; Magraner MJ; Coret F; Sanz MA; Montalbán X; Casanova B
Mult Scler; 2009 Nov; 15(11):1303-10. PubMed ID: 19825889
[TBL] [Abstract][Full Text] [Related]
9. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia.
Todisco E; Testi AM; Avvisati G; Moleti ML; Cedrone M; Cimino G; Mancini F; Amadori S; Mandelli F
Leukemia; 1995 Sep; 9(9):1583-5. PubMed ID: 7658728
[TBL] [Abstract][Full Text] [Related]
10. A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.
Cattaneo C; Almici C; Borlenghi E; Motta M; Rossi G
Leukemia; 2003 May; 17(5):985-6. PubMed ID: 12750718
[No Abstract] [Full Text] [Related]
11. Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: cytogenetic and molecular features.
Au WY; Lam CC; Ma ES; Man C; Wan T; Kwong YL
Hum Pathol; 2001 Jan; 32(1):126-9. PubMed ID: 11172306
[TBL] [Abstract][Full Text] [Related]
12. DNA topoisomerase II in therapy-related acute promyelocytic leukemia.
Mistry AR; Felix CA; Whitmarsh RJ; Mason A; Reiter A; Cassinat B; Parry A; Walz C; Wiemels JL; Segal MR; Adès L; Blair IA; Osheroff N; Peniket AJ; Lafage-Pochitaloff M; Cross NC; Chomienne C; Solomon E; Fenaux P; Grimwade D
N Engl J Med; 2005 Apr; 352(15):1529-38. PubMed ID: 15829534
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
Ellis R; Boggild M
Mult Scler; 2009 Apr; 15(4):505-8. PubMed ID: 19251838
[TBL] [Abstract][Full Text] [Related]
14. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes.
Hasan SK; Buttari F; Ottone T; Voso MT; Hohaus S; Marasco E; Mantovani V; Garagnani P; Sanz MA; Cicconi L; Bernardi G; Centonze D; Lo-Coco F
Neurology; 2011 Mar; 76(12):1059-65. PubMed ID: 21346221
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone.
Novoselac AV; Reddy S; Sanmugarajah J
Leukemia; 2004 Sep; 18(9):1561-2. PubMed ID: 15215874
[No Abstract] [Full Text] [Related]
16. Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.
Bosca I; Pascual AM; Casanova B; Coret F; Sanz MA
Neurology; 2008 Aug; 71(6):457-8. PubMed ID: 18678830
[No Abstract] [Full Text] [Related]
17. Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Ammatuna E; Montefusco E; Pacilli M; Divona M; Ardiri D; Centonze D; Lo-Coco F
Leuk Lymphoma; 2009 Jul; 50(7):1217-8. PubMed ID: 19479616
[No Abstract] [Full Text] [Related]
18. [Therapy-related acute promyelocytic leukemia with a t(9;22)(q34;q11) and t(15;17)(q22;q11 to approximately 12) subclone].
Mochiduki Y; Muramoto S
Rinsho Ketsueki; 2005 Nov; 46(11):1218-22. PubMed ID: 16440807
[TBL] [Abstract][Full Text] [Related]
19. Secondary chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia.
Jeddi R; Gouider E; Benneji H; Mnif S; Ben Abid H; Belhadjali Z; Meddeb B
Pathol Biol (Paris); 2008 May; 56(3):162-3. PubMed ID: 18178033
[TBL] [Abstract][Full Text] [Related]
20. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.
Hasan SK; Mays AN; Ottone T; Ledda A; La Nasa G; Cattaneo C; Borlenghi E; Melillo L; Montefusco E; Cervera J; Stephen C; Satchi G; Lennard A; Libura M; Byl JA; Osheroff N; Amadori S; Felix CA; Voso MT; Sperr WR; Esteve J; Sanz MA; Grimwade D; Lo-Coco F
Blood; 2008 Oct; 112(8):3383-90. PubMed ID: 18650449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
